Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (13934)	1/13/2005 1:09:44 AM
From: axial	Read Replies (1) \| Respond to of 14101

Cal, it looks like Dimethaid - and Pennsaid - are getting some favourable attention. About time, too! Pennsaid goes off-patent in Canada this year. Possible outcomes: A - Price no longer controlled by PMRB. Price drop, and re-evaluation by formularies? Or, will they finally accept the argument that Pennsaid avoids cost of pills, without data, and without a price drop? Changing the price in Canada means changing it everywhere. There are linkages, and "baskets" of reference prices. B - At some point in the future, should we look for a reformulation and new patent on Pennsaid? Possibly. C - When WF10 returns to the stage, possibly a Euro trial. At the same time (posted last year) - Dimethaid seeks status as a Euro domestic supplier (facilities in Wanzleben, trials in Europe), and applies for Pennsaid approval in Germany and France. Thus, Dimethaid gets around the Franco-German trade barriers to products for which they have domestic equivalents. Could this happen? I think it could. We ain't dead yet. Jim